• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.

    9/3/24 6:22:25 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    SC 13D/A 1 d861715dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D/A

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)

    (Amendment No. 3)*

     

     

    GoodRx Holdings, Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    38246G108

    (CUSIP Number)

    Carolina A. Picazo

    Spectrum Equity

    140 New Montgomery St., 20th Floor,

    San Francisco, CA 94105

    (415) 464-4600

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 29, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

     

     

    1

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes’).

     

     

     


     1.    

     Names of Reporting Persons

     

     Spectrum Equity VII, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     25,835,983

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     25,835,983

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     25,835,983

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     20.11%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 128,478,172 shares of Class A Common Stock (“Class A Shares”) outstanding, based upon 98,583,716 Class A Shares outstanding as of July 30, 2024 as reported on the Issuer’s Form 10-Q filed on August 8, 2024 (the “10-Q”), as increased by 3,989,323 Class A Shares distributed in the August 2024 Distribution, as defined below, and as further increased by 25,905,133 shares of Class B Common Stock, which are convertible into Class A Shares on a one-to-one basis (“Class B Shares”), held by the Reporting Persons following the August 2024 Distribution, as defined below.


     1.    

     Names of Reporting Persons

     

     Spectrum Equity Associates VII, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     25,835,983

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     25,835,983

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     25,835,983

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     20.11%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 128,478,172 Class A Shares outstanding, based upon 98,583,716 Class A Shares outstanding as of July 30, 2024 as reported on the 10-Q, as increased by 3,989,323 Class A Shares distributed in the August 2024 Distribution, as defined below, and as further increased by 25,905,133 Class B Shares held by the Reporting Persons following the August 2024 Distribution, as defined below.


     1.    

     Names of Reporting Persons

     

     Spectrum VII Investment Managers’ Fund, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     44,223

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     44,223

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     44,223

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     0.03%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 128,478,172 Class A Shares outstanding, based upon 98,583,716 Class A Shares outstanding as of July 30, 2024 as reported on the 10-Q, as increased by 3,989,323 Class A Shares distributed in the August 2024 Distribution, as defined below, and as further increased by 25,905,133 Class B Shares held by the Reporting Persons following the August 2024 Distribution, as defined below.


     1.    

     Names of Reporting Persons

     

     Spectrum VII Co-Investment Fund, L.P.

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     24,927

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     24,927

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     24,927

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     0.02%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Calculated assuming 128,478,172 Class A Shares outstanding, based upon 98,583,716 Class A Shares outstanding as of July 30, 2024 as reported on the 10-Q, as increased by 3,989,323 Class A Shares distributed in the August 2024 Distribution, as defined below, and as further increased by 25,905,133 Class B Shares held by the Reporting Persons following the August 2024 Distribution, as defined below.


     1.    

     Names of Reporting Persons

     

     SEA VII Management, LLC

     2.  

     Check The Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds

     

     OO

     5.  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.  

     Shared Voting Power

     

     25,905,133

        9.  

     Sole Dispositive Power

     

     0

       10.  

     Shared Dispositive Power

     

     25,905,133

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     25,905,133

    12.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (9)

     

     20.11%(1)

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    (1)

    Calculated assuming 128,478,172 Class A Shares outstanding, based upon 98,583,716 Class A Shares outstanding as of July 30, 2024 as reported on the 10-Q, as increased by 3,989,323 Class A Shares distributed in the August 2024 Distribution, as defined below, and as further increased by 25,905,133 Class B Shares held by the Reporting Persons following the August 2024 Distribution, as defined below.


    Item 1. Security and Issuer

    The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.

    This Amendment No. 3 (“Amendment No. 3”) is being filed by the undersigned to amend the Schedule 13D filed with the SEC on June 1, 2021, as amended by Amendment No. 1, filed with the SEC on November 21, 2023 and Amendment No. 2, filed with the SEC on March 8, 2024 (the “Original 13D” and, as amended by Amendment No. 3, the “Schedule 13D”) relating to shares of common stock (the “Common Stock”), of GoodRx Holdings, Inc., a Delaware corporation (the “Issuer”), whose principal executive office is located at 2701 Olympic Boulevard, Santa Monica, California 90404. Except as set forth herein, the Original 13D is unmodified and remains in full force and effect. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Original 13D.

    Item 2. Identity and Background

    The Schedule 13D is being filed by the following entities (each a “Reporting Person” and collectively, the “Reporting Persons”):

     

      1.

    Spectrum Equity VII, L.P. (“SE VII”)

     

      2.

    Spectrum Equity Associates VII, L.P. (“Spectrum Equity Associates”)

     

      3.

    Spectrum VII Investment Managers’ Fund, L.P. (“Spectrum VII Investment Managers’ Fund”)

     

      4.

    Spectrum VII Co-Investment Fund, L.P. (“Spectrum VII Co-Investment Fund”)

     

      5.

    SEA VII Management, LLC (“Management LLC”)

    Information with respect to the members and executive officers of Management LLC (collectively, the “Related Persons”), including the name, business address, present principal occupation or employment and citizenship of each of the Related Persons is listed on the attached Schedule A, which is incorporated herein by reference.

    During the last five years, neither the Reporting Persons nor any Related Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended to include the following at the end thereof:

    On August 29, 2024, SE VII distributed 3,989,323 shares of the Issuer’s Class A Common Stock pro rata to its limited partners for no consideration (the “August 2024 Distribution”). Following the August 2024 Distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers’ Fund, L.P. made open market sales of an aggregate of 10,677 shares of the Issuer’s Class A Common Stock for net proceeds of $83,922.05.

    Item 5. Interest in the Securities of the Issuer

    Items 5(a), (b) and (c) of the Schedule 13D is hereby amended and restated as follows:

    (a) and (b)

    All such ownership percentages of the securities reported in this Schedule 13D were calculated assuming 128,478,172 Class A Shares outstanding, based upon 98,583,716 Class A Shares outstanding as of July 30, 2024 as reported on the 10-Q, as increased by 3,989,323 Class A Shares distributed in the August 2024 Distribution and as further increased by 25,905,133 Class B Shares held by the Reporting Persons following the August 2024 Distribution.


    The aggregate 25,905,133 securities reported in this statement, which constitute 20.16% of the outstanding Class A Shares, are held by the Reporting Persons on an as-converted basis as follows: SE VII is the holder of record of 25,835,983 Class A Shares, Spectrum VII Investment Managers’ Fund is the holder of record of 44,223 Class A Shares, and Spectrum VII Co-Investment Fund is the holder of record of 24,927 Class A Shares.

    The general partner of SE VII is Spectrum Equity Associates. The general partner of each of Spectrum VII Investment Managers’ Fund, Spectrum VII Co-Investment Fund and Spectrum Equity Associates is Management LLC. Brion B. Applegate, Christopher T. Mitchell, Victor E. Parker, Jr., Benjamin C. Spero, Ronan Cunningham, Peter T. Jensen, Stephen M. LeSieur, Brian Regan and Michael W. Farrell may be deemed to share voting and dispositive power over the securities held by SE VII, Spectrum VII Investment Managers’ Fund and Spectrum VII Co-Investment Fund. Each of these individuals disclaims beneficial ownership of such securities.

    In addition, as discussed in Item 2 above, by virtue of the agreements made pursuant to the Stockholders Agreement, the Stockholders acknowledge and agree that they are acting as a group for purposes of Rule 13d-3 under the Exchange Act. Shares beneficially owned by the other Stockholders are not the subject of this Schedule 13D and accordingly, none of the other Stockholders are included as reporting persons herein.

    (c)

    During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Class A Common Stock.

    Item 7. Materials to be Filed as Exhibits

     

    Exhibit 1

    Joint Filing Agreement, filed with the SEC as Exhibit 1 to the Original 13D on May 19, 2021.


    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

    Dated: September 3, 2024

     

    Spectrum Equity VII, L.P.
    By: Spectrum Equity Associates VII, L.P., its general partner
    By: SEA VII Management, LLC, its general partner
    By:  

    /s/ Carolina A. Picazo

    Name:   Carolina A. Picazo
    Title:   Chief Administrative Officer & Chief Compliance Officer
    Spectrum Equity Associates VII, L.P.
    By: SEA VII Management, LLC, its general partner
    By:  

    /s/ Carolina A. Picazo

    Name:   Carolina A. Picazo
    Title:   Chief Administrative Officer & Chief Compliance Officer
    Spectrum VII Investment Managers’ Fund, L.P.
    By: SEA VII Management, LLC, its general partner
    By:  

    /s/ Carolina A. Picazo

    Name:   Carolina A. Picazo
    Title:   Chief Administrative Officer & Chief Compliance Officer
    Spectrum VII Co-Investment Fund, L.P.
    By: SEA VII Management, LLC, its general partner
    By:  

    /s/ Carolina A. Picazo

    Name:   Carolina A. Picazo
    Title:   Chief Administrative Officer & Chief Compliance Officer


    SEA VII Management, LLC
    By:  

    /s/ Carolina A. Picazo

    Name:   Carolina A. Picazo
    Title:   Chief Administrative Officer & Chief Compliance Officer
    Get the next $GDRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    Mizuho initiated coverage on GoodRx with a new price target

    Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

    12/4/24 7:38:07 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Raymond James with a new price target

    Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

    8/9/24 7:30:17 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

    Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic® has been made available to patients at this self-pay price.

    8/18/25 9:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rey-Giraud Agnes gifted 75,219 shares and received a gift of 75,219 shares, decreasing direct ownership by 47% to 85,448 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/19/25 6:07:00 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin covered exercise/tax liability with 1,719 shares and converted options into 4,804 shares, increasing direct ownership by 2% to 137,292 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/15/25 6:36:46 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 6% to 134,207 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/8/25 5:15:01 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:20:51 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:12:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by GoodRx Holdings Inc.

    SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    7/3/25 7:23:11 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve

    7/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports First Quarter 2025 Results

    First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

    5/7/25 4:13:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology